Cencora’s CEO Steve Collis to retire, Robert Mauch to take reins as president/CEO
Cencora announced that Steven Collis will retire as president and CEO of the company and transition to the role of executive chair of the Cencora board of directors, effective Oct. 1. Robert Mauch, current chief operating officer of Cencora, will succeed Collis as president and CEO, and also will be appointed as a member of the company's board, effective the same date.
“Steve’s 30-year career at Cencora has been characterized by purpose-driven leadership, delivering phenomenal growth in domestic and international markets, diversification of the business, and the successful launch of a global brand that positions the company for even greater success. Since Steve’s appointment as CEO in 2011, Cencora has delivered tremendous financial growth, with the company’s annual revenue more than tripling to exceed $250 billion,” said Mark Durcan, lead independent director of Cencora.
Durcan added, “Under his leadership, Cencora has grown into the global healthcare leader it is today with its 46,000 team members spanning over 50 countries. Throughout his tenure, Steve has been a visionary leader, forging the company’s leadership in specialty while championing team member growth and development. On behalf of the entire board, I thank Steve for his considerable contributions to our business, and look forward to continuing to benefit from his deep industry knowledge and expertise as executive chairman.”
[Read more: Walgreens Boots Alliance sells AmerisourceBergen shares for $1B of proceeds]
“In my 30 years with Cencora, including 13 years as CEO, it has been my privilege to lead our company as we have delivered robust growth, made strategic investments and forged key partnerships. I am particularly proud of the position we are in today where Cencora is characterized by our strong industry leadership position, intellectual confidence, and best-in-class talent and customer relationships,” Collis said.
Collis continued, “Together, the Cencora team has built extraordinary relationships across our industry, expanded the breadth of our innovative pharmaceutical solutions and grown our global footprint, furthering our ability to advance our purpose of creating healthier futures. Bob and I have worked closely for nearly two decades, and I am proud that he will be the third CEO in our company’s 23-year history. He has been an integral partner in shaping and implementing our strategy and embodies our purpose-driven culture. The company will benefit from his unique background, expertise and proven leadership as he assumes the role of CEO. I am excited to support Bob and the team as they continue to advance our position at the center of health care.”
“Today’s announcement is consistent with the Board’s deliberate and thoughtful approach to succession planning,” Durcan continued. “Bob has experience across all aspects of our business and has helped lead Cencora’s evolution to become a united, global provider of pharmaceutical-centric healthcare solutions. The Board is confident that he will continue to build on Cencora’s momentum to drive value for our team, customers, partners and shareholders.”
[Read more: AmerisourceBergen changes name to Cencora]
“I am honored to succeed Steve as president and CEO of Cencora and am appreciative of his leadership and mentorship over the many years we have worked together,” Mauch said. “Throughout my years at Cencora, I have been excited and motivated by our teams’ ability to adapt and innovate to address the needs of our partners and I look forward to continuing to drive our pharmaceutical-centric strategy forward, supported by our talented team members and unwavering commitment to our purpose.”